Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/7319| Наслов: | Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience | Authors: | Crvenkova, Simonida Ivkovski, Lj Dimovski, A Kaeva, B |
Issue Date: | 2012 | Journal: | Prilozi | Abstract: | The aim of this study was to evaluate tumour response, QoL and adverse effects of erlotinib, EGFR tyrosine kinase inhibitor (TKI), as a second line therapy for patients with EGFR mutation in NSCLC, after failure of previous first-line therapy. | URI: | http://hdl.handle.net/20.500.12188/7319 | ISSN: | 0351-3254 |
| Appears in Collections: | Faculty of Medicine: Journal Articles |
Прикажи целосна запис
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.